EP0262448A1 - Dérivés d'imidazolylguanidine, leur procédé de préparation et les médicaments contenant ces composés - Google Patents

Dérivés d'imidazolylguanidine, leur procédé de préparation et les médicaments contenant ces composés Download PDF

Info

Publication number
EP0262448A1
EP0262448A1 EP87112906A EP87112906A EP0262448A1 EP 0262448 A1 EP0262448 A1 EP 0262448A1 EP 87112906 A EP87112906 A EP 87112906A EP 87112906 A EP87112906 A EP 87112906A EP 0262448 A1 EP0262448 A1 EP 0262448A1
Authority
EP
European Patent Office
Prior art keywords
propyl
pyridin
imidazol
mono
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87112906A
Other languages
German (de)
English (en)
Other versions
EP0262448B1 (fr
Inventor
Armin Dr. Buschauer
Helmut Dr.Dipl.-Chem. Schickaneder
Peter Dr.Dipl.-Chem. Mörsdorf
Walter Prof.Dr.Dr. Schunack
Gert Dr. Baumann
Kurt Dr. Henning Ahrens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heumann Pharma GmbH and Co
Original Assignee
Heumann Pharma GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heumann Pharma GmbH and Co filed Critical Heumann Pharma GmbH and Co
Priority to AT87112906T priority Critical patent/ATE70533T1/de
Publication of EP0262448A1 publication Critical patent/EP0262448A1/fr
Application granted granted Critical
Publication of EP0262448B1 publication Critical patent/EP0262448B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the invention relates to new imidazolylguanidine derivatives which, owing to their agonistic action on histamine H 2 receptors and partly because of their additional hi-antagonistic receptor activity, can be used in diseases of the heart, in certain forms of hypertension and in arterial occlusive diseases.
  • Histamine as a specific stimulator of the H2 receptors, due to its H 1 agonistic effect, triggers negative, sometimes fatal effects in the form of bronchospasm and anaphylactic shock, so that the therapeutic use of histamine is not possible in the treatment of the diseases mentioned.
  • the invention is therefore based on the object of compensating for the unfavorable effects of histamine and of providing better and more selective HrAgonists, in which the harmful side effects caused by an H1-agonistic active component may possibly occur. can be avoided by an additional hi-antagonistic activity profile.
  • the invention relates to imidazolylguanidine derivatives of the general formula I.
  • R the grouping means, where R 1 is an unsubstituted or a mono- to trisubstituted phenyl group or an unsubstituted or a mono- to trisubstituted pyridine ring
  • R 2 is a hydrogen atom, a C 1 -C 3 -alkyl group, an optionally mono- to trisubstituted phenyl group , an unsubstituted or a mono- to trisubstituted benzyl group or an unsubstituted or a mono- to trisubstituted heteroarylmethyl group and
  • n has the value 2, 3 or 4, or in which R is the grouping means in which R 3 represents an unsubstituted or a mono- to trisubstituted phenyl group or an unsubstituted or a mono- to trisubstituted pyridine ring
  • R can be the grouping mean.
  • R ' represents an unsubstituted or a mono- to trisubstituted phenyl group, preferably a doubly substituted phenyl group.
  • substitution there are in particular 1 to 3 halogen atoms, such as fluorine, chlorine or bromine atoms, preferably fluorine or chlorine atoms, 1 to 3 C 1 -C 3 alkyl groups, preferably methyl or ethyl groups, and 1 to 3 C, C 3 alkoxy groups, such as methoxy or ethoxy groups, into consideration.
  • Single substitution and double substitution are preferred.
  • the substitution in the 4-position and in the case of double substitution the substitution in the 3-position and 4-position of the phenyl ring is preferred.
  • the trifluoromethyl group can be used as a further substituent on the phenyl ring.
  • the phenyl group is preferably substituted with 1 to 3 trifluoromethyl groups, particularly preferably a trifluoromethyl group.
  • the binding is preferably in the 4-position of the phenyl ring.
  • the substituent R 1 can furthermore be an unsubstituted mono- to trisubstituted pyridine ring.
  • the pyridine ring is preferably mono- or disubstituted.
  • substituents for the pyridine ring are halogen atoms, such as fluorine, chlorine or bromine atoms, preferably fluorine or chlorine atoms, very particularly preferably fluorine atoms, C 1 -C 3 -alkyl groups, such as methyl or ethyl groups, and C 1 -C 3 -alkoxy groups , such as methoxy, ethoxy or propoxy groups, preferably methoxy groups.
  • the pyridine ring indicated by R 1 can be linked to the nitrogen atom in the R group in the 2-, 3- or 4-position of the pyridine ring, the 2 or 3 position being preferred.
  • the linkage in the 2-position of the pyridine ring is particularly preferred.
  • R2 stands for a hydrogen atom, a C 1 -C 3 -alkyl group, in particular a methyl, ethyl or propyl group, a phenyl group which may be unsubstituted or optionally mono- to trisubstituted, in particular mono- or disubstituted, a benzyl group which may be unsubstituted or a-bs trisubstituted, or a heteroarylmethyl group which may be unsubstituted or mono- to trisubstituted.
  • the phenyl group indicated by R 2 can be substituted in the same manner and with the same substituents as described above in connection with the substitution of the phenyl group indicated by R 1 .
  • the benzyl group can be substituted with 1 to 3, preferably 2 halogen atoms, such as fluorine, chlorine or bromine atoms, preferably chlorine or fluorine atoms, or C 1 -C 3 alkoxy groups, such as methoxy or ethoxy groups, preferably methoxy groups be.
  • the substituent is preferably bonded in the para position to the methylene group, while in the case of double substitution the 3 and 4 positions of the benzyl group are preferred.
  • the trifluoromethyl group can be considered as a further substituent for the benzyl group indicated by R 2 , it being possible for the benzyl group to be substituted by 1 to 3 trifluoromethyl groups. Single substitution with the trifluoromethyl group is preferred, this being preferably bonded in the para position to the benzyl group.
  • R 2 represents a heteroarylmethyl group
  • this group is preferably a thiophenylmethyl, furanmethyl or pyridinmethyl group.
  • the heteroarylmethyl group can also be unsubstituted or preferably mono- to trisubstituted. Single or double substitution is preferred.
  • Halogen atoms such as fluorine, chlorine or bromine atoms, C 1 -C 3 alkyl groups, such as methyl or ethyl groups, and linear C 1 -C 3 alkoxy groups, such as methoxy groups, are suitable as substituents.
  • n has the value 2, 3 or 4, with the value 3 being preferred.
  • R can continue the grouping mean.
  • R 3 can be an unsubstituted or a mono- to trisubstituted phenyl group or a one to three-substituted pyridine ring.
  • substitution there are in particular 1 to 3 halogen atoms, such as fluorine, chlorine or bromine atoms, preferably fluorine or chlorine atoms, 1 to 3 C 1 -C 3 -alkyl groups, preferably methyl or ethyl groups, and 1 to 3 C 1 -C 4 3 alkoxy groups, such as methoxy or ethoxy groups, into consideration.
  • halogen atoms such as fluorine, chlorine or bromine atoms, preferably fluorine or chlorine atoms
  • 1 to 3 C 1 -C 3 -alkyl groups preferably methyl or ethyl groups
  • 1 to 3 C 1 -C 4 3 alkoxy groups such as methoxy or ethoxy groups
  • the substitution in the 4-position and in the case of double substitution the substitution in the 3-position and 4-position of the phenyl ring is preferred.
  • the trifluoromethyl group and the hydroxyl group can be considered as further substitution of the phenyl ring.
  • the phenyl group is preferably substituted by a trifluoromethyl group or a hydroxy group, the binding preferably taking place in the 4-position of the phenyl ring.
  • the substituent R 3 can furthermore be an unsubstituted or a mono- to trisubstituted pyridine ring, preferably an unsubstituted pyridine ring or a monosubstituted pyridine ring.
  • substituents of the pyridine ring include halogen atoms such as fluorine, chlorine or bromine atoms, preferably fluorine, or chlorine atoms, most preferably fluorine atoms, C 1 -C 3 alkyl groups such as methyl or ethyl groups, and Ci-C 3 alkoxy , such as methoxy, ethoxy or propoxy groups, preferably methoxy groups.
  • halogen atoms such as fluorine, chlorine or bromine atoms, preferably fluorine, or chlorine atoms, most preferably fluorine atoms, C 1 -C 3 alkyl groups such as methyl or ethyl groups, and Ci-C 3 alkoxy , such as methoxy, ethoxy or propoxy groups, preferably methoxy groups.
  • the pyridine ring indicated by R 3 can be linked to the nitrogen atom in the R group in the 2-, 3- or 4-position of the pyridine ring, the 2 or 3 position being preferred.
  • the linkage in the 2-position of the pyridine ring is particularly preferred.
  • R 4 represents a hydrogen atom or an unsubstituted or a mono- to trisubstituted phenyl group. In the case of substitution, the phenyl group indicated by R 4 is substituted in the same manner as the phenyl group indicated by R 3 .
  • R 5 represents a hydrogen atom or a methyl or hydroxyl group.
  • Z represents a single bond or an oxygen atom, while p has the value 2 or 3.
  • X furthermore denotes a hydrogen atom or a benzoyl group.
  • m has the value 2 or 3, preferably 3, and R 'represents a hydrogen atom or a methyl group, preferably a hydrogen atom.
  • IR in the general formula stands for the grouping where R 1 is an unsubstituted or mono- to triple, preferably single or double, very preferably an unsubstituted, pyridine ring.
  • the substituents can be halogen atoms, such as a fluorine, chlorine or bromine atom, preferably a fluorine or chlorine atom, in particular a fluorine atom, C 1 -C 3 alkyl groups, such as a methyl or ethyl group, or C 1 -C 3 alkoxy groups, such as a methoxy, ethoxy or propoxy group, preferably a methoxy group.
  • the pyridine ring can be linked to the nitrogen atom in R in the 2-, 3- or 4-position of the pyridine ring, the 2 or 3 position being preferred.
  • the linkage in the 2-position of the pyridine ring is very particularly preferred.
  • R 2 represents an optionally mono- to trisubstituted benzyl group or an unsubstituted or mono- to trisubstituted heteroarylmethyl group.
  • the benzyl group may, for example, have one to three, preferably two, halogen atoms, such as, for example, a fluorine, chlorine or bromine atom, preferably a chlorine or fluorine atom, or a C 1 -C 3 alkoxy group, such as a methoxy or ethoxy group a methoxy group, the substituent preferably being bonded in the para position to the methylene group. In the case of a double substitution, the 3 and 4 positions of the benzyl group are preferred.
  • the CF 3 group can be used as a further substituent.
  • the trifluoromethyl group is preferably bonded in the para position of the benzyl group.
  • the heteroarylmethyl group is, for example, a thiophenmethyl, furanmethyl or pyridinmethyl group, which may have one or two halogen atoms, such as fluorine, chlorine or bromine atoms, a C 1 -C 3 alkyl group, for example a methyl or ethyl group, or one linear C 1 -C 3 alkoxy group, for example a methoxy group; is substituted.
  • halogen atoms such as fluorine, chlorine or bromine atoms
  • a C 1 -C 3 alkyl group for example a methyl or ethyl group
  • one linear C 1 -C 3 alkoxy group for example a methoxy group
  • n has the value 2, 3 or 4, preferably 2 or 3.
  • X and R ' preferably represent a hydrogen atom, while m has the value 2 or 3, preferably 3.
  • R represents the grouping where R 1 is an unsubstituted or mono- to trisubstituted phenyl ring.
  • the phenyl ring can have 1 to 3 halogen atoms, such as fluorine, chlorine or bromine atoms, preferably fluorine or chlorine atoms, C 1 -C 3 -alkyl groups, preferably methyl or ethyl groups, or Ci-C 3 -alkoxy groups, such as methoxy or Ethoxy groups, which are preferably in the 4-position or in the case of a double substitution in the 3-and 4-position.
  • Another preferred substituent is the trifluoromethyl group, which is preferably attached in the 4-position of the phenyl ring.
  • R 2 represents an unsubstituted or a mono- to trisubstituted heteroarylmethyl group, such as a thiophenmethyl, furanmethyl or pyridinmethyl group, preferably a thiophenmethyl group.
  • the index n has the value 2, 3 or 4, preferably 2 or 3, the value 2 being particularly preferred.
  • X and R ' are preferably a hydrogen atom, while m is 2 or 3, preferably 3.
  • R represents the grouping where R 1 is an unsubstituted or mono- to trisubstituted, preferably an unsubstituted, pyridine ring and R 2 is a hydrogen atom. If the pyridine ring is substituted several times, one to three identical or different substituents from the group halogen atoms, linear C 1 -C 3 alkyl groups and linear C 1 -C 3 alkoxy groups are suitable.
  • the pyridine ring can be linked to the nitrogen atom in positions 2, 3 or 4, positions 2 and 3, particularly position 2, being preferred.
  • n has the value 2, 3 or 4, preferably the value 3.
  • X and R ' preferably represent a hydrogen atom, while m has the value 2 or 3, preferably 3.
  • IR in the general formula stands for the grouping where R 1 is an unsubstituted or mono- to trisubstituted pyridine ring and R 2 is an unsubstituted or mono- to trisubstituted phenyl ring.
  • the substituents are preferably halogen atoms, for example fluorine, chlorine or bromine atoms, preferably fluorine or chlorine atoms, linear C 1 -C 3 alkoxy groups, such as methoxy or ethoxy groups, preferably a methoxy group, or linear Ci-C 3 alkyl groups, for example a methyl or ethyl group, preferably a methyl group.
  • the pyridine ring can be linked to the nitrogen atom in R in positions 2, 3 and 4, position 2 being particularly preferred. In this case, any substituents present are in positions 3 and / or 5.
  • phenyl ring is simply substituted, then the substitution in the 4-position is preferred. Substitution with a chlorine or fluorine atom in the 4-position is very particularly preferred. If the phenyl ring is substituted twice, then the substitutions in the 3 and 4 positions are preferred. Also preferred as the substituent is the trifluoromethyl group, which is preferably bonded in position 4 of the phenyl ring.
  • X and R ' preferably denote a hydrogen atom, n has the value 2, 3 or 4, preferably the value 3, while the value 3 is preferred for m.
  • IR in the general formula stands for the grouping wherein R 3 and R 4 , which may be the same or different, each represent an unsubstituted or mono- to trisubstituted phenyl group.
  • suitable substituents are halogen atoms, such as fluorine-chlorine or bromine atoms, linear C 1 -C 3 alkoxy groups, such as preferably methoxy groups, or linear C 1 -C 3 alkyl groups, preferably methyl or ethyl groups.
  • Halogen atoms in particular fluorine or chlorine atoms, are preferred as substituents which are in the 2-, 3- or preferably in the 4-position or in the case of double substitution in the 3- / 4-position or the 3/5-position, preferably in the 3- / 4- Position of the phenyl ring.
  • the trifluomethyl group can be considered as a further preferred substituent, the 4-position in the phenyl ring being preferred.
  • R 5 represents a hydrogen atom or a methyl group
  • Z represents a single bond
  • p has the value 2 or 3, preferably the value 2.
  • X and R ' preferably represent a hydrogen atom, while m preferably has the value 3 .
  • R represents the grouping where R 3 represents an unsubstituted or mono- to trisubstituted phenyl group.
  • R 3 represents an unsubstituted or mono- to trisubstituted phenyl group.
  • halogen atoms such as fluorine, chlorine or bromine atoms, in particular fluorine or chlorine atoms
  • Ci-C r alkoxy groups for example a methoxy, ethoxy or propoxy group
  • linear C 1 -C 3 alkyl groups such as methyl or ethyl groups, or a hydroxyl group are preferred as substituents.
  • R 3 denotes a 4-fluorophenyl, 4-chlorophenyl-3,4- / 3,5-difluorophenyl or 3,4- / 3,5-dichlorophenyl group is very particularly preferred.
  • the dual substitution for R 3 also includes, for example, a 4-fluoro-3-chlorophenyl or 4-chloro-3-fluorophenyl group.
  • the trifluoromethyl group is also preferred as a substituent. It can be bonded in the 2-, 3- or 4-position, preferably in the 3- and 4-position, very particularly preferably in the 4-position, of the phenyl ring.
  • R 4 denotes an unsubstituted or mono- to trisubstituted pyridine ring which can be bonded via the 2-, 3- or 4-position, the 2-and 3-positions being particularly preferred.
  • Halogen atoms for example fluorine, chlorine or bromine atoms, preferably bromine atoms, C 1 -C 3 alkyl groups such as, methyl or ethyl groups, preferably methyl groups, or C I -C 3 alkoxy groups, such as methoxy or Ethoxy groups, especially methoxy groups, into consideration. If the pyridine ring is linked via the 2 position, as indicated above as being particularly preferred, then any substituents present are in the 3 and / or 4 position of the pyridine ring.
  • R 5 represents a hydrogen atom or a methyl or hydroxy group, preferably a hydrogen atom
  • Z represents a single bond
  • p has the value 2 or 3, particularly preferably the value 2.
  • X represents a hydrogen atom
  • R ' represents a hydrogen atom or a methyl group , preferably a hydrogen atom
  • m has the value 2 or 3, in particular the value 3.
  • IR in the general formula stands for the grouping where R 3 represents an unsubstituted or mono- to trisubstituted pyridine ring and R 4 and R 5 each represent a hydrogen atom.
  • the pyridine ring is preferably unsubstituted, but can also be substituted by halogen atoms, such as fluorine, chloro or bromine atoms, C 1 -C 3 -alkyl groups, such as methyl, ethyl or propyl groups, or C 1 -C 3 alkoxy groups, such as methoxy- , Ethoxy or propoxy groups, mono- to trisubstituted.
  • Z stands for a single bond, p for the value 2 or 3, with the value 3 being preferred.
  • X and R 'each represent a hydrogen atom, while m preferably has the value 3.
  • IR in the general formula stands for the grouping where R 3 and R 4 , which may be the same or different, each independently represent an unsubstituted or mono- to trisubstituted phenyl ring.
  • the substituents on the phenyl ring which are preferably in the 3- or 4-position, in particular in the 4-position, can be halogen atoms, such as fluorine or chlorine atoms, C 1 -C 3 -alkyl groups, such as, for example, methyl, ethyl or propyl groups , or C 1 -C 3 alkoxy groups, preferably methoxy groups.
  • R 5 represents a hydrogen atom
  • Z represents an oxygen atom
  • p can have the value 2 or 3, preferably 2.
  • X and R ' preferably denote a hydrogen atom, while the value 3 is preferred for m.
  • the compounds obtained according to the individual process variants are isolated and purified in the usual way, for example by chromatographic procedures, recrystallization, etc.
  • the compounds obtained in the individual process variants can optionally be converted into their physiologically acceptable salt.
  • the invention therefore also includes the physiologically acceptable salts of this compound.
  • these salts can, for example, with mineral acids, such as hydrochloric acid, hydrobromic acid or hydroiodic acid, phosphoric acid, metaphosphoric acid, nitric acid or sulfuric acid, or with organic acids, such as formic acid, acetic acid, propionic acid, phenylacetic acid, tartaric acid, citric acid, fumaric acid, methanesulfonic acid, embonic acid etc. , are formed.
  • the compounds of the invention can be formulated for administration in any manner.
  • the invention therefore also includes medicinal products which contain at least one compound according to the invention for use in human or veterinary medicine.
  • Such drugs can conventionally be made using one or more pharmaceutical carriers or diluents.
  • the compounds according to the invention can therefore be formulated for oral, buccal, topical, parenteral or rectal administration.
  • the drug may be in the form of, for example, tablets, capsules, powders, solutions, syrups or suspensions, which have been prepared in a conventional manner using acceptable diluents.
  • the drug can take the form of tablets or sachets that have been formulated in a conventional manner.
  • the compounds of the invention can be formulated for parenteral administration by bolus injection or continuous infusion.
  • Formulations for injection can be in unit dose form as ampoules or in multi-dose containers with added preservatives.
  • the medicaments can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and they can contain formulation auxiliaries such as suspending, stabilizing and / or dispersing agents.
  • the active ingredient can also be in powder form for reconstitution with a suitable carrier, for example sterile, pyrogen-free water, before use.
  • a suitable carrier for example sterile, pyrogen-free water
  • the compounds according to the invention can also be formulated for rectal preparations, for example suppositories or retention enemas, which contain, for example, conventional suppository bases, such as cocoa butter or other glycerides.
  • the compounds according to the invention can be formulated in a conventional manner as ointments, creams, gels, lotions, powders or sprays.
  • a suitable daily dose of compounds according to the invention is 1 to 4 doses up to a total of 5 mg to 1 g / day, depending on the condition of the patient.
  • the compounds according to the invention are distinguished by a novel, previously unknown and described overall pharmacological activity.
  • the new structure class according to the invention shows both a hi-antagonistic and a hragonistic active component.
  • the following pharmacological results show this.
  • a recognized method for determining hi-antagonistic activity is the determination of the pk values in vitro (Arunlakshana, O. and Schild, HO (1959), "Some Quantitative Uses of Drug Antagonists", Br.J. Pharmac.Chemother. 14, 48 -58).
  • H r agonistic Aktivat2011 pDrWerte
  • the method according to van Rossum, JM (1963) "Cumulative Dose-Response Curves. 11 Technique for the Making of Dose-Response Curves in isolated organ and the evalution of Drug parameter" , Arch.Intern.Pharmacodyn.Therap. 143, 299-307.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP87112906A 1986-09-15 1987-09-03 Dérivés d'imidazolylguanidine, leur procédé de préparation et les médicaments contenant ces composés Expired - Lifetime EP0262448B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87112906T ATE70533T1 (de) 1986-09-15 1987-09-03 Imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863631334 DE3631334A1 (de) 1986-09-15 1986-09-15 Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3631334 1986-09-15

Publications (2)

Publication Number Publication Date
EP0262448A1 true EP0262448A1 (fr) 1988-04-06
EP0262448B1 EP0262448B1 (fr) 1991-12-18

Family

ID=6309606

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87112906A Expired - Lifetime EP0262448B1 (fr) 1986-09-15 1987-09-03 Dérivés d'imidazolylguanidine, leur procédé de préparation et les médicaments contenant ces composés

Country Status (17)

Country Link
US (1) US4912119A (fr)
EP (1) EP0262448B1 (fr)
JP (1) JPS6383072A (fr)
KR (1) KR950010326B1 (fr)
AT (1) ATE70533T1 (fr)
AU (1) AU606882B2 (fr)
CA (1) CA1249829A (fr)
DE (2) DE3631334A1 (fr)
DK (1) DK165982C (fr)
ES (1) ES2040720T3 (fr)
GR (1) GR3003388T3 (fr)
HU (1) HU212302B (fr)
IE (1) IE59278B1 (fr)
IL (1) IL83804A (fr)
NZ (1) NZ221611A (fr)
PT (1) PT85697B (fr)
ZA (1) ZA876163B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339208A1 (fr) * 1988-04-26 1989-11-02 HEUMANN PHARMA GMBH & CO Dérivés de 6-oxopyridazine, procédé pour leur préparation et médicaments contenant ces composés
EP0448765A1 (fr) * 1990-03-30 1991-10-02 HEUMANN PHARMA GMBH & CO Uitlisation de dérivés de la guanidine pour la fabrication d'un médicament à activité antagoniste du neuropeptide Y
WO1992015567A1 (fr) * 1991-02-27 1992-09-17 Seed Capital Investment (Sci) B.V. Derives d'imidazoles possedant une activite agoniste ou antagoniste sur le recepteur de l'histamine h3
EP0526395A1 (fr) * 1991-07-22 1993-02-03 Zyma SA Dérivés arylalkylaminés, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2686084A1 (fr) * 1992-01-10 1993-07-16 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5837718A (en) * 1991-02-27 1998-11-17 Seed Capital Investment (Sci) B.V. Imidazole-derivatives having agonistic or antagonistic activity on the histamine H3-receptor
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3579000D1 (de) * 1985-04-02 1990-09-06 Heumann Pharma Gmbh & Co Imidazolylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
DE3726381A1 (de) * 1987-08-07 1989-02-16 Heumann Pharma Gmbh & Co Guanidincarbonsaeureester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6127343A (en) * 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
ZA974147B (en) * 1996-05-14 1997-11-14 Novo Nordisk As Somatostatin agonists and antagonists.
WO1998018786A1 (fr) * 1996-10-31 1998-05-07 Novo Nordisk A/S Agonistes et antagonistes contraints de somatostatine
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
WO2000078319A1 (fr) 1999-06-21 2000-12-28 Bristol-Myers Squibb Company Derives de dihydropyrazines utilises en tant qu'antagonistes des npy
DE60136284D1 (de) * 2000-09-20 2008-12-04 Schering Corp Substituierte imidazole als histamine h1 und h3 agonisten oder antagonisten
KR101892241B1 (ko) * 2015-11-06 2018-08-27 송재근 유분 분리 장치

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433625A1 (de) * 1973-07-13 1975-01-30 Smith Kline French Lab Harnstoff-derivate, verfahren zu ihrer herstellung und arzneimittel
EP0199845A1 (fr) * 1985-04-02 1986-11-05 HEUMANN PHARMA GMBH & CO Dérivés d'imidazolylalkylguanidine, leur procédé de préparation et compositions les contenant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL49528A (en) * 1975-05-21 1980-11-30 Smith Kline French Lab Imidazolyl(or thiazolyl)methylthio(or butyl)guanidine or thiourea derivatives,their preparation and pharmaceutical compositions comprising them
DE2835695A1 (de) * 1977-08-29 1979-03-15 Yamanouchi Pharma Co Ltd Neue heterocyclische verbindungen, verfahren zu ihrer herstellung und arzneimittel, die diese enthalten
DK221081A (da) * 1980-05-31 1981-12-01 Smith Kline French Lab Fremgangsmaade til fremstilling af heterocyklylalkylanidiner mellemprodukter til anvendelse ved denne fremgangsmaade og en fremgangsmaade til fremstilling af disse mellemprodukter
JPH0660096B2 (ja) * 1983-11-04 1994-08-10 富山化学工業株式会社 アミン誘導体またはその塩を含有する抗潰瘍剤
DE3528214A1 (de) * 1985-08-06 1987-02-12 Heumann Ludwig & Co Gmbh Arylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3726381A1 (de) * 1987-08-07 1989-02-16 Heumann Pharma Gmbh & Co Guanidincarbonsaeureester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433625A1 (de) * 1973-07-13 1975-01-30 Smith Kline French Lab Harnstoff-derivate, verfahren zu ihrer herstellung und arzneimittel
EP0199845A1 (fr) * 1985-04-02 1986-11-05 HEUMANN PHARMA GMBH & CO Dérivés d'imidazolylalkylguanidine, leur procédé de préparation et compositions les contenant

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339208A1 (fr) * 1988-04-26 1989-11-02 HEUMANN PHARMA GMBH & CO Dérivés de 6-oxopyridazine, procédé pour leur préparation et médicaments contenant ces composés
US4968683A (en) * 1988-04-26 1990-11-06 Heumann Pharma Gmbh & Co. 6-oxo-pyridazine derivatives, a process for their preparation and medicaments containing these compounds
EP0448765A1 (fr) * 1990-03-30 1991-10-02 HEUMANN PHARMA GMBH & CO Uitlisation de dérivés de la guanidine pour la fabrication d'un médicament à activité antagoniste du neuropeptide Y
WO1992015567A1 (fr) * 1991-02-27 1992-09-17 Seed Capital Investment (Sci) B.V. Derives d'imidazoles possedant une activite agoniste ou antagoniste sur le recepteur de l'histamine h3
US5837718A (en) * 1991-02-27 1998-11-17 Seed Capital Investment (Sci) B.V. Imidazole-derivatives having agonistic or antagonistic activity on the histamine H3-receptor
EP0526395A1 (fr) * 1991-07-22 1993-02-03 Zyma SA Dérivés arylalkylaminés, procédé pour leur préparation et compositions pharmaceutiques les contenant
US5212187A (en) * 1991-07-22 1993-05-18 Zyma Sa Pyridyl alkylamine compounds which are useful against histamine h1 and h2 receptors
FR2686084A1 (fr) * 1992-01-10 1993-07-16 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
WO1993014070A3 (fr) * 1992-01-10 1993-08-19 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques
US5559113A (en) * 1992-01-10 1996-09-24 Institut National De La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications
US5708171A (en) * 1992-01-10 1998-01-13 Institut National De La Sante Et De La Recherche Medicale Imidazole derivatives for pharmaceutical use
USRE37303E1 (en) * 1992-01-10 2001-07-31 Institut National Del La Sante Et De La Recherche Medicale Imidazole compounds and their therapeutic applications

Also Published As

Publication number Publication date
PT85697B (pt) 1990-08-31
HU212302B (en) 1996-05-28
US4912119A (en) 1990-03-27
ES2040720T3 (es) 1993-11-01
IL83804A0 (en) 1988-02-29
DK165982C (da) 1993-07-26
PT85697A (de) 1987-10-01
ATE70533T1 (de) 1992-01-15
IL83804A (en) 1993-02-21
KR950010326B1 (ko) 1995-09-14
ZA876163B (en) 1988-02-23
JPS6383072A (ja) 1988-04-13
IE59278B1 (en) 1994-02-09
DE3775319D1 (de) 1992-01-30
AU7767287A (en) 1988-03-17
HUT56352A (en) 1991-08-28
IE872463L (en) 1988-03-15
KR880003937A (ko) 1988-06-01
AU606882B2 (en) 1991-02-21
DK165982B (da) 1993-02-22
DK472887A (da) 1988-03-16
NZ221611A (en) 1989-09-27
DE3631334A1 (de) 1988-03-17
DK472887D0 (da) 1987-09-10
CA1249829A (fr) 1989-02-07
EP0262448B1 (fr) 1991-12-18
GR3003388T3 (en) 1993-02-17

Similar Documents

Publication Publication Date Title
EP0262448B1 (fr) Dérivés d'imidazolylguanidine, leur procédé de préparation et les médicaments contenant ces composés
DD200371A5 (de) Verfahren zur herstellung von 2,4-disubstituierten thiazolen
DD201589A5 (de) Verfahren zur herstellung von aminothiadiazolen
EP0199845B1 (fr) Dérivés d'imidazolylalkylguanidine, leur procédé de préparation et compositions les contenant
DE2433625A1 (de) Harnstoff-derivate, verfahren zu ihrer herstellung und arzneimittel
DE3522579C2 (de) Neue 1,4-Dihydropyridin-Derivate und Salze derselben, Verfahren zur Herstellung derselben und pharmazeutische Mittel mit einem Gehalt derselben
DE3782621T2 (de) Imidazol-derivate, verfahren zu ihrer herstellung, pharmazeutische zubereitungen, welche diese enthalten, verwendung dieser zur herstellung therapeutisch wirksamer arzneimittel und zwischenprodukte, welche beim herstellungsverfahren entstehen.
DE2344833A1 (de) Guanidine, ihre salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0004561B1 (fr) Composés d'urée et d'amide, procédé pour leur préparation, compositions pharmaceutiques les contenant et leur utilisation pour préparer des compositions pharmaceutiques
DE3615180C2 (de) Disubstituierte 1,4-Piperazinylderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
DE3728491A1 (de) Dihydropyridazinon-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4246263A (en) Antiinflammatory and immunoregulatory pyrimidines, their method of use and pharmaceutical compositions
DE69805033T2 (de) Tetrazolderivate als LTD4 und H1 Antagonisten
EP0093252A2 (fr) Dérivés de thiométhylpyridine, procédé pour leur préparation et médicaments les contenant
EP0124630B1 (fr) Dérivés de pyrimidinothioalkyle pyridine, procédé pour leur préparation et médicaments contenant ces composés
US4060621A (en) Pyridyl alkylguanidine compounds
EP0302164B1 (fr) Esters d'acides guanidinecarboxyliques, procédés pour leur préparation et médicaments contenant ces composés
EP0158789A1 (fr) Dérivés de diamine, procédé pour leur préparation et médicaments contenant ces composés
EP0141119A2 (fr) Dérivés de sulfénamide, procédé pour leur préparation et médicaments contenant ces composés
EP0154721A1 (fr) Dérivés d'alcanols, procédés pour leur préparation et médicaments contenant ces composés
DE69114644T2 (de) 4(5)-Imidazole fähig zur Inhibierung von Aromatase.
DE3528215A1 (de) Heteroarylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3512084A1 (de) Guanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0250725B1 (fr) Dérivés de 1,4-dihydropyridine, procédés pour leur préparation et médicaments les contenant
DE3528214A1 (de) Arylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19880809

17Q First examination report despatched

Effective date: 19891024

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 70533

Country of ref document: AT

Date of ref document: 19920115

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3775319

Country of ref document: DE

Date of ref document: 19920130

ET Fr: translation filed
GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3003388

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2040720

Country of ref document: ES

Kind code of ref document: T3

EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 87112906.0

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19950801

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19950818

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19950823

Year of fee payment: 9

Ref country code: DE

Payment date: 19950823

Year of fee payment: 9

Ref country code: CH

Payment date: 19950823

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19950829

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19950831

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19950904

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19950905

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19950929

Year of fee payment: 9

Ref country code: AT

Payment date: 19950929

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960903

Ref country code: GB

Effective date: 19960903

Ref country code: AT

Effective date: 19960903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960904

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960904

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19960930

Ref country code: FR

Effective date: 19960930

Ref country code: CH

Effective date: 19960930

Ref country code: BE

Effective date: 19960930

BERE Be: lapsed

Owner name: HEUMANN PHARMA G.M.B.H. & CO.

Effective date: 19960930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19970331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19970401

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19960903

REG Reference to a national code

Ref country code: GR

Ref legal event code: MM2A

Free format text: 3003388

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19970401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19970603

EUG Se: european patent has lapsed

Ref document number: 87112906.0

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 19971011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050903